EPID-06. The Key LARGO study: Building an international resource for glioblastoma epidemiology

Abstract Despite decades of epidemiological research, no glioblastoma risk factors have been identified that explain substantial risk. Prior studies often rely on single- or multi-center recruitment, which is costly and limits generalizability to the broader glioblastoma patient population. To address this and increase the diversity of glioblastoma patients in epidemiological research, we have launched the Key LARGO study (NCT06625684, Key Longitudinal Associations with Risk and Glioblastoma Outcomes), an ongoing observational study of glioblastoma patients and their caregivers. Key LARGO uses web-based enrollment and at-home biospecimen collection via mailed Tasso+ kits for self-collection of blood and serum. Participants also complete a detailed, online survey (available in English or Spanish) on life history and health-related quality of life (FACT-Br). Primary caregivers are enrolled to help report patient outcomes, including vital status. This study is a collaboration between the Preston Robert Tisch Brain Tumor Center, the Glioblastoma Research Organization, and StacheStrong. Recruitment for Key LARGO began on December 10, 2025. As of May 29, 2025, 79 patients and 30 caregivers have consented. Of these, 63 consented for blood collection, 53 received kits, and 32 (60%) have returned samples. Fifty-seven participants (72%) have completed the full study survey. Participants are 51% male, with a median age of 49 years (range 38-59) at time of diagnosis, that were diagnosed between 2007 and 2025. Most (96%) identified as white. Nine percent identified as Ashkenazi Jewish, and 5% identified as Hispanic or Latino. Blood collection kits have been returned from the United States, Canada, Italy, and the United Kingdom. Key LARGO demonstrates the feasibility of web-based recruitment and remote biospecimen collection in glioblastoma research and provides a scalable model for increasing geographic and demographic diversity in epidemiological studies.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2025-11-01
DOI
https://doi.org/10.1093/neuonc/noaf201.0738
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

EPID-06. The Key LARGO study: Building an international resource for glioblastoma epidemiology

Quinn T. Ostrom, Kyle M. Walsh, Courtney E. Wimberly
Neuro-Oncology
Glioma Diagnosis and Treatment
article

EPID-06. The Key LARGO study: Building an international resource for glioblastoma epidemiology

Quinn T. Ostrom, Kyle M. Walsh, Courtney E. Wimberly
article en

Abstract

Abstract Despite decades of epidemiological research, no glioblastoma risk factors have been identified that explain substantial risk. Prior studies often rely on single- or multi-center recruitment, which is costly and limits generalizability to the broader glioblastoma patient population. To address this and increase the diversity of glioblastoma patients in epidemiological research, we have launched the Key LARGO study (NCT06625684, Key Longitudinal Associations with Risk and Glioblastoma Outcomes), an ongoing observational study of glioblastoma patients and their caregivers. Key LARGO uses web-based enrollment and at-home biospecimen collection via mailed Tasso+ kits for self-collection of blood and serum. Participants also complete a detailed, online survey (available in English or Spanish) on life history and health-related quality of life (FACT-Br). Primary caregivers are enrolled to help report patient outcomes, including vital status. This study is a collaboration between the Preston Robert Tisch Brain Tumor Center, the Glioblastoma Research Organization, and StacheStrong. Recruitment for Key LARGO began on December 10, 2025. As of May 29, 2025, 79 patients and 30 caregivers have consented. Of these, 63 consented for blood collection, 53 received kits, and 32 (60%) have returned samples. Fifty-seven participants (72%) have completed the full study survey. Participants are 51% male, with a median age of 49 years (range 38-59) at time of diagnosis, that were diagnosed between 2007 and 2025. Most (96%) identified as white. Nine percent identified as Ashkenazi Jewish, and 5% identified as Hispanic or Latino. Blood collection kits have been returned from the United States, Canada, Italy, and the United Kingdom. Key LARGO demonstrates the feasibility of web-based recruitment and remote biospecimen collection in glioblastoma research and provides a scalable model for increasing geographic and demographic diversity in epidemiological studies.

Neuro-OncologyVol. 27(Supplement_5)
Duke University (US)
Openalex Percentile: Top 51%
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

EPID-06. The Key LARGO study: Building an international resource for glioblastoma epidemiology — Quinn T. Ostrom, Kyle M. Walsh, et al. · Neuro-Oncology (2025) | TGRS Research Map | TGRS